This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.
The FDA recommended the use of Zydelig ( idelalisib) in combination with Roche's Rituxan ( rituximab) to treat patients with relapsed chronic lymphocytic leukaemia.
FDA sets standard review for Gilead's idelalisib in NHL. Comes despite accelerated review for drug's use in chronic lymphocytic leukaemia. ... The US Food and Drug Administration ( FDA) has started its review of Gilead Sciences' marketing application for
Just last week the European Medicines Agency ( EMA) issued recommendations to both Janssen's Imbruvica ( ibrutinib) and Gilead's Zydelig ( idelalisib) in CLL indications.
Arzerra ( ofatumumab) in April 2014 and Gilead Science's Zydelig ( idelalisib) just this month.
The recommendation for Gilead's Zydelig ( idelalisib) covers its use in the treatment of patients with chronic lymphocytic leukaemia and patients with refractory follicular lymphoma.
its PI3K inhibitor idelalisib, which was superior to MabThera in a CLL trial reported last year.
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.